Dateline City:
KENILWORTH, N.J.
Phase 2 Data Presentations at The Liver Meeting Detail SVR12 Rates from Two Studies as Well as SVR8 Rates in Patients for Whom Direct-Acting Antiviral Treatment Previously Failed
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today announced the presentation of results from three Phase 2 clinical
trials evaluating MK-3682B (MK-3682/grazoprevir/ruzasvir1),
the companys investigational all-oral, triple-combination regimen for
the treatment of chronic hepatitis C (HCV) infection (informally
referred to as MK3).
Language:
English
Contact:
Media:Doris Li, 908-246-5701orSarra Herzog, 201-669-6570orInvestors:Teri Loxam, 908-740-1986orAmy Klug, 908-740-1898
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more